Rohto Pharmaceutical Co.,Ltd.
“Medium- to Long-Term Growth Strategy 2026” ～ Rolling Update of “Rohto Group Medium- to Long-Term Growth Strategy 2025–2035” and Announcement Regarding Financial Forecasts for Fiscal Year 2031 ～
Announced a rolling update of the medium- to long-term growth strategy and newly set financial forecasts for FY2031. Targets include net sales of 464 billion yen, operating income of 59.8 billion yen, operating margin of 12.9%, overseas sales ratio of 56%, and a payout ratio of 40%.
Key Figures
- FY2031 Net Sales: 464 hundred million yen
- FY2031 Operating Income: 59.8 hundred million yen
- FY2031 Operating Margin: 12.9%
- Overseas Sales Ratio: 56%
- Payout Ratio: 40%
AI要約
Update of Medium- to Long-Term Strategy
The Rohto Group operates the "Medium- to Long-Term Growth Strategy 2025–2035" on a rolling-update basis and has reorganized financial forecasts with FY2031 set as the new target year. The strategy centers on strengthening business earnings power, deepening technical and product capabilities, and expanding the medical business foundation, aiming to achieve sustainable growth and improved financial soundness through strategy execution.
FY2031 Financial Targets and Shareholder Returns
The FY2031 targets were announced as net sales of 464 hundred million yen, operating income of 59.8 hundred million yen, operating margin of 12.9%, overseas sales ratio of 56%, and payout ratio of 40%. The company revised the prior FY2030 forecasts and emphasizes maintaining financial soundness metrics such as ROE above 10% while balancing growth investments and shareholder returns.
Rohto Pharmaceutical Co.,Ltd.
Company overview · Stock price · Financial data · All IR
